Ojji D B, Opie L H, Lecour S, Lacerda L, Adeyemi O M, Sliwa K
1] Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria [2] Faculty of Health Sciences, Department of Medicine, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa.
Faculty of Health Sciences, Department of Medicine, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa.
J Hum Hypertens. 2014 Jul;28(7):432-7. doi: 10.1038/jhh.2013.130. Epub 2014 Jan 9.
Soluble ST2 is a biomarker of cardiomyocyte stretch that is useful in the diagnosis and prognosis of coronary artery disease. Its role in the field of hypertension and hypertensive heart failure (HHF) has not yet been well investigated. We studied the effect of left ventricular remodelling on the concentration of soluble ST2 in a cohort of 210 subjects with hypertension (HT). Left ventricular hypertrophy (LVH) was considered present when echocardiographic left ventricular mass indexed for height in metres (m) was greater than 46.2 g m(-1 2.7) in women and 49.2 g m(-1 2.7) in men. Subjects were subdivided into three groups: those without LVH (HT, n = 83); those with LVH (hypertension with left ventricular hypertrophy (HTLVH), n = 50) and those with HHF, n=77). Plasma ST2 and NT-pro BNP were measured using electrochemiluminescence type immunoassay. Subjects with HHF had higher plasma ST2 concentrations compared to HTLVH (134.7 ± 57.3 ng ml(-1) versus 23.0 ± 8.3 ng ml(-1), P < 0.001) and those with HT (134.7 ± 57.3 ng ml(-1) versus 14.5 ± 4.9 ng ml(-1), P < 0.0001). NT-pro BNP levels were similar when HTLVH was compared with HT (P = 0.68), but subjects with HHF had significantly higher NT-pro BNP compared to HTLVH (P < 0.0002). Soluble ST2 had strong correlation with clinical and echocardiograhic parameters, and correlated well with NT-pro BNP (r = 0.41, P < 0.0001). Plasma ST2 is a useful biomarker in not only differentiating HHF from HT with or without LVH, but also distinguishes hypertensive LVH from HT without LVH.
可溶性ST2是心肌细胞拉伸的生物标志物，对冠状动脉疾病的诊断和预后有帮助。其在高血压及高血压性心力衰竭（HHF）领域的作用尚未得到充分研究。我们在210名高血压（HT）受试者队列中研究了左心室重构对可溶性ST2浓度的影响。当以身高（米）为指数的超声心动图左心室质量在女性中大于46.2 g m⁻¹.²⁷、在男性中大于49.2 g m⁻¹.²⁷时，认为存在左心室肥厚（LVH）。受试者被分为三组：无LVH者（HT，n = 83）；有LVH者（高血压合并左心室肥厚（HTLVH），n = 50）和HHF者（n = 77）。采用电化学发光免疫分析法测定血浆ST2和NT-pro BNP。与HTLVH（23.0±8.3 ng/ml vs 134.7±57.3 ng/ml，P < 0.001）及HT（14.5±4.9 ng/ml vs 134.7±57.3 ng/ml，P < 0.0001）相比，HHF受试者的血浆ST2浓度更高。HTLVH与HT相比，NT-pro BNP水平相似（P = 0.68），但与HTLVH相比，HHF受试者的NT-pro BNP显著更高（P < 0.0002）。可溶性ST2与临床和超声心动图参数密切相关，且与NT-pro BNP相关性良好（r = 0.41，P < 0.0001）。血浆ST2不仅是区分HHF与有或无LVH的HT的有用生物标志物，还能区分有LVH的高血压与无LVH的HT。
